Oral Health in Breast Cancer Survivors on Aromatase Inhibitors

Inclusion Criteria: Postmenopausal as defined by NCCN (any of the following) * Prior bilateral oophorectomy * Age equal to or greater then 60 years of age * Age less then 60 and amenorrheic for 12 or more months in the absence of chemotherapy, tamoxifen, toremifen or ovarian suppression and FSH and estradiol in the postmenopausal range * If taking tamoxifen or toremifen and age less then 60y, then FSH and plasma estradiol level in postmenopausal ranges Informed consent- Individuals capable of consenting and self administering the survey instrument Dentate- At least 15 teeth present. AI users: * Diagnosis of BCa- Histologic confirmed diagnosis of BCa: Stage 0, I, II, or III with no evidence of metastatic disease. * Treatment- AI as clinically indicated (AI may be anastrozole, exemestane or letrozole) \> 1 month. Subjects may have had prior tamoxifen or raloxifene. Subjects may have had chemotherapy and/or radiation therapy. Must be within the first year of consecutive AI therapy. If a subject started AI, discontinued, then restarted, they will be accepted into the study. Controls: * No Diagnosis of cancer.- Patients must not have a diagnosis of any cancer (Not including a history of localized thyroid or skin cancer). Exclusion Criteria: Medical history * Metastatic BCa (AI treated group: fully resected locally recurrent disease is permitted if the patient has been rendered without evidence of disease). * Significant psychiatric illness/social situations that would preclude completion of questionnaire. Medications * Chronic medications known to affect the periodontal status (calcium antagonist, anti-convulsives, immunosuppressives (\> prednisone 7.5mg daily). NSAIDS and bisphosphonates are permitted. * Premedication- Conditions that require antibiotic therapy will be evaluated on a case-by-case basis. (Patients taking prophylaxis for joint replacements will not be excluded.)